TRANEXAMIC VERSUS KLIGMAN IN MELASMA TREATMENT

Melasma is a common dermatological condition that may presents a great therapeuticchallenge to treat. The specific aim of the present study was to evaluate the efficacy andsafety of topical tranexamic Acid (TA 3 %) loaded chitosan microparticles (TA-CsMPs)as compared with modified Kligman’s formula. A total 24 females with melasma in ournonrandomized comparison study were classified into 2 groups. Group (I) females advisedto apply topical 3 % TA-Cs microgel twice daily, while group (II) was received Kligmanregimen once daily at night. A modified Melasma Area Severity Index (m-MASI) scorewas used to evaluate patients clinically once weekly for 6 weeks and followed up for 3more months after treatment completion. Dermal type of melasma, with a lateral or centrofacial pattern of distribution and Fitzpatrick type III was found mostly in patients. The mMASI score was significantly lower in comparison to the baseline in both investigatedgroups. Beside the adverse reaction as redness, irritation, or burning associated with topicalKligman formula, TA-CsMPs regimen has superior efficacy and safety in melasmatreatment. Taken together, our current outcomes demonstrated that topical 3% TA-CsMPsis an innovative, effective, and could be a potentially promising safe alternative with goodpatient acceptance for melasma treatment.